Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Considering The Value Of Cardiovascular Data And Real World Evidence In Diabetes

Executive Summary

Cardiovascular outcomes trials headlined the recent ADA meeting. Scrip spoke with executives from Novo, Boehringer, AstraZeneca and Merck at the conference about the value of CV data and real world evidence in an era when managing diabetes is about much more than lowering blood glucose.


Related Content

Novo's Tresiba Significantly Reduces Hypoglycemia Versus Lantus In DEVOTE
Merck & Co, Pfizer Ertugliflozin Combo Data Beef Up Profile
Novo Nordisk Sharpens Its Outlook But Warns Risks Remain Later In 2017
Lilly Shows Diabetes Dominance, But Will It Last?
Cardiovascular Benefits of SGLT2 Inhibitors: A Class Effect?
BI/Lilly's Jardiance Is First Diabetes Drug With CV Benefit Claim
Tresiba Vs. Lantus: Novo Nordisk Scores A Win In Second Head-To-Head
Novo Nordisk Says Global Payer Pressure Limits Price Rises


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts